The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Drug Interactions

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Drug Interactions


Psychiatry related information on Drug Interactions


High impact information on Drug Interactions


Chemical compound and disease context of Drug Interactions


Biological context of Drug Interactions


Anatomical context of Drug Interactions


Associations of Drug Interactions with chemical compounds


Gene context of Drug Interactions

  • Although expression of the CYP3A4 gene is known to be induced in response to a variety of compounds, the mechanism underlying this induction, which represents a basis for drug interactions in patients, has remained unclear [21].
  • The development and use of P-gp inhibitors with minimal or absent CYP3A inhibitory effects should decrease the impact of drug interactions on the therapeutic use of such compounds [36].
  • In this manner, induction of CYP3A5 may contribute to the overall importance of this P450 in drug metabolism and drug interactions [37].
  • Interindividual variability and drug interactions affecting intestinal transporter and hepatic CYP3A and CYP2B6 activity may alter methadone disposition [38].
  • In conclusion, activation of PXR and CAR and especially the resulting induction of CYP3A4 and MDR1 demonstrate that artemisinin has a higher risk of potential drug interactions than anticipated previously [39].

Analytical, diagnostic and therapeutic context of Drug Interactions


  1. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside. Presant, C.A., Vietti, T.J., Valeriote, F., Coulter, D.M. J. Natl. Cancer Inst. (1981) [Pubmed]
  2. Chemotherapy-induced interstitial pneumonitis during treatment of small cell anaplastic lung cancer. Zimmerman, M.S., Ruckdeschel, J.C., Hussain, M. J. Clin. Oncol. (1984) [Pubmed]
  3. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. Fetell, M.R., Grossman, S.A., Fisher, J.D., Erlanger, B., Rowinsky, E., Stockel, J., Piantadosi, S. J. Clin. Oncol. (1997) [Pubmed]
  4. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. Moyle, G.J., Lloyd, M., Reynolds, B., Baldwin, C., Mandalia, S., Gazzard, B.G. AIDS (2001) [Pubmed]
  5. Problems associated with medical treatment of peptic ulcer disease. Zimmerman, T.W. Am. J. Med. (1984) [Pubmed]
  6. Indinavir: a review of its use in the management of HIV infection. Plosker, G.L., Noble, S. Drugs (1999) [Pubmed]
  7. Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Chudnow, R.S., Dewey, R.B., Lawson, C.R. Arch. Neurol. (1997) [Pubmed]
  8. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Nordberg, A., Svensson, A.L. Drug safety : an international journal of medical toxicology and drug experience. (1998) [Pubmed]
  9. A risk-benefit assessment of moclobemide in the treatment of depressive disorders. Norman, T.R., Burrows, G.D. Drug safety : an international journal of medical toxicology and drug experience. (1995) [Pubmed]
  10. A review of rivastigmine: a reversible cholinesterase inhibitor. Williams, B.R., Nazarians, A., Gill, M.A. Clinical therapeutics. (2003) [Pubmed]
  11. Drug interaction between thyroxine and lovastatin. Demke, D.M. N. Engl. J. Med. (1989) [Pubmed]
  12. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS. Bach, M.C. N. Engl. J. Med. (1987) [Pubmed]
  13. A digoxin-antibiotic drug interaction. Doherty, J.E. N. Engl. J. Med. (1981) [Pubmed]
  14. Adenine arabinoside and allopurinol--possible adverse drug interaction. Friedman, H.M. N. Engl. J. Med. (1981) [Pubmed]
  15. Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man. Pettinger, W.A., Mitchell, H.C. N. Engl. J. Med. (1975) [Pubmed]
  16. The effect of allopurinol on cyclophosphamide antitumor activity. Alberts, D.S., van Daalen Wetters, T. Cancer Res. (1976) [Pubmed]
  17. Apparent quinidine-induced digoxin toxicity after withdrawal of pentobarbital: a case of sequential drug interactions. Chapron, D.J., Mumford, D., Pitegoff, G.I. Arch. Intern. Med. (1979) [Pubmed]
  18. Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein? Phillips, E.J., Rachlis, A.R., Ito, S. AIDS (2003) [Pubmed]
  19. Elucidation of the nifedipine-quinidine interaction. Munger, M.A., Jarvis, R.C., Nair, R., Kasmer, R.J., Nara, A.R., Urbancic, A., Green, J.A. Clin. Pharmacol. Ther. (1989) [Pubmed]
  20. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Hsu, A., Granneman, G.R., Cao, G., Carothers, L., el-Shourbagy, T., Baroldi, P., Erdman, K., Brown, F., Sun, E., Leonard, J.M. Clin. Pharmacol. Ther. (1998) [Pubmed]
  21. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. Lehmann, J.M., McKee, D.D., Watson, M.A., Willson, T.M., Moore, J.T., Kliewer, S.A. J. Clin. Invest. (1998) [Pubmed]
  22. Valproic acid in epilepsy: clinical and pharmacological effects. Mattson, R.H., Cramer, J.A., Williamson, P.D., Novelly, R.A. Ann. Neurol. (1978) [Pubmed]
  23. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cho, Y.L., Christensen, C., Saunders, D.E., Lawrence, W.D., Deppe, G., Malviya, V.K., Malone, J.M. Cancer Res. (1991) [Pubmed]
  24. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions. Sörgel, F., Kinzig, M. Am. J. Med. (1993) [Pubmed]
  25. Systematic overview of warfarin and its drug and food interactions. Holbrook, A.M., Pereira, J.A., Labiris, R., McDonald, H., Douketis, J.D., Crowther, M., Wells, P.S. Arch. Intern. Med. (2005) [Pubmed]
  26. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Iwahori, T., Matsuura, T., Maehashi, H., Sugo, K., Saito, M., Hosokawa, M., Chiba, K., Masaki, T., Aizaki, H., Ohkawa, K., Suzuki, T. Hepatology (2003) [Pubmed]
  27. Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Tanabe, J., Tregellas, J.R., Martin, L.F., Freedman, R. Biol. Psychiatry (2006) [Pubmed]
  28. Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. Oda, Y., Kharasch, E.D. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  29. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. Lampen, A., Zhang, Y., Hackbarth, I., Benet, L.Z., Sewing, K.F., Christians, U. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  30. Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein. Chatterjee, M., Harris, A.L. Br. J. Cancer (1990) [Pubmed]
  31. Potentiation of hypoglycemic effect of sulfonylureas by halofenate. Jain, A.K., Ryan, J.R., McMahon, F.G. N. Engl. J. Med. (1975) [Pubmed]
  32. Membrane surface potential changes may alter drug interactions: an example, acetylcholine and curare. Van der Kloot, W.G., Cohen, I. Science (1979) [Pubmed]
  33. Drug interactions at the GABA receptor-ionophore complex. Olsen, R.W. Annu. Rev. Pharmacol. Toxicol. (1982) [Pubmed]
  34. Carbamazepine-erythromycin interaction. Case studies and clinical significance. Wroblewski, B.A., Singer, W.D., Whyte, J. JAMA (1986) [Pubmed]
  35. Mechanism of the cardiotoxic actions of terfenadine. Woosley, R.L., Chen, Y., Freiman, J.P., Gillis, R.A. JAMA (1993) [Pubmed]
  36. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Wandel, C., Kim, R.B., Kajiji, S., Guengerich, P., Wilkinson, G.R., Wood, A.J. Cancer Res. (1999) [Pubmed]
  37. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). Burk, O., Koch, I., Raucy, J., Hustert, E., Eichelbaum, M., Brockmöller, J., Zanger, U.M., Wojnowski, L. J. Biol. Chem. (2004) [Pubmed]
  38. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Kharasch, E.D., Hoffer, C., Whittington, D., Sheffels, P. Clin. Pharmacol. Ther. (2004) [Pubmed]
  39. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Burk, O., Arnold, K.A., Nussler, A.K., Schaeffeler, E., Efimova, E., Avery, B.A., Avery, M.A., Fromm, M.F., Eichelbaum, M. Mol. Pharmacol. (2005) [Pubmed]
  40. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Baughman, R.A., Kapoor, S.C., Agarwal, R.K., Kisicki, J., Catella-Lawson, F., FitzGerald, G.A. Circulation (1998) [Pubmed]
  41. Characterization of human cytochrome P450 enzymes. Guengerich, F.P. FASEB J. (1992) [Pubmed]
  42. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Ma, J., Pulfer, S., Li, S., Chu, J., Reed, K., Gallo, J.M. Cancer Res. (2001) [Pubmed]
  43. Absence of drug interaction between heparin and nitroglycerin. Randomized placebo-controlled crossover study. Bode, V., Welzel, D., Franz, G., Polensky, U. Arch. Intern. Med. (1990) [Pubmed]
  44. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Hutson, P.R., Love, R.R., Havighurst, T.C., Rogers, E., Cleary, J.F. Clin. Cancer Res. (2005) [Pubmed]
WikiGenes - Universities